All In Biotech

Drug Trial Radar · NCT04642924

SGM-101 in Locally Advanced and Recurrent Rectal Cancer

Multicenter, Open-label, Controlled, Parallel Arms Clinical Study on the Performance of SGM-101, a Fluorochrome-labeled Anti-carcino-embryonic Antigen (CEA) Monoclonal Antibody, for Locally Advanced or Recurrent Rectal Cancer Patients Undergoing Curative Surgery

Last checked: Nov 19, 2026Latest source record: Nov 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

203

Planned (sponsor's estimate)

Start

Oct 22, 2019

Primary completion

Oct 2021

Study completion Oct 2023

Sponsor

Lead sponsor
Leiden University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Erasmus Medical Center; Amsterdam UMC, location VUmc; Catharina Ziekenhuis Eindhoven; Medical Center Haaglanden; Surgimab; Quest Medical Imaging; Centre for Human Drug Research, Netherlands
First posted
Nov 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Near-infrared fluorescence-guided oncologic surgery (EGOS) with the use of a tumor specific tracer (SGM-101) developed by Surgimab can provide valuable intra-operative information about tumor location and extensiveness, which can be difficult to detect with conventional visual and tactile feedback. Hence, this information could aid in intra-operative decision making and therewith foster complete resection margins and less extensive surgery. Subsequently, this may drastically improve patient care by improving oncologic outcome.

Conditions

  • Rectal Cancer
  • Recurrent Rectal Cancer

Interventions

  • SGM-101Drug

    Fluorescence-guided surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Resection statusTime frame: 10 days post surgery

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Amsterdam University Medical Center

    Amsterdam, Netherlands · Recruiting

  • Catharina Hospital Eindhoven

    Eindhoven, Netherlands · Recruiting

  • Erasmus Medical Center

    Rotterdam, Netherlands · Recruiting

  • Haaglanden Medisch Centrum

    The Hague, Netherlands · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.